Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Probing Anisotropic Surface Properties of Illite by Atomic Force Microscopy.

Shao H, Chang J, Lu Z, Luo B, Grundy JS, Xie G, Xu Z, Liu Q.

Langmuir. 2019 May 21;35(20):6532-6539. doi: 10.1021/acs.langmuir.9b00270. Epub 2019 May 1.

PMID:
31008608
2.

Unraveling Interaction Mechanisms between Molybdenite and a Dodecane Oil Droplet Using Atomic Force Microscopy.

Feng L, Manica R, Grundy JS, Liu Q.

Langmuir. 2019 May 7;35(18):6024-6031. doi: 10.1021/acs.langmuir.9b00203. Epub 2019 Apr 24.

PMID:
30991805
3.

No effect on QT intervals of mipomersen, a 2'-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects.

Yu RZ, Gunawan R, Li Z, Mittleman RS, Mahmood A, Grundy JS, Singleton W, Geary R, Wang Y.

Eur J Clin Pharmacol. 2016 Mar;72(3):267-75. doi: 10.1007/s00228-015-1992-y. Epub 2015 Dec 9.

PMID:
26645588
4.

Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modifications.

Yu RZ, Grundy JS, Henry SP, Kim TW, Norris DA, Burkey J, Wang Y, Vick A, Geary RS.

Mol Ther Nucleic Acids. 2015 Jan 20;4:e218. doi: 10.1038/mtna.2014.69.

5.

Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates.

Rigo F, Chun SJ, Norris DA, Hung G, Lee S, Matson J, Fey RA, Gaus H, Hua Y, Grundy JS, Krainer AR, Henry SP, Bennett CF.

J Pharmacol Exp Ther. 2014 Jul;350(1):46-55. doi: 10.1124/jpet.113.212407. Epub 2014 Apr 30.

6.

Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen.

Li Z, Hard ML, Grundy JS, Singh T, von Moltke LL, Boltje I.

J Cardiovasc Pharmacol. 2014 Aug;64(2):164-71. doi: 10.1097/FJC.0000000000000101.

PMID:
24691275
7.

Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers.

Flaim JD, Grundy JS, Baker BF, McGowan MP, Kastelein JJ.

J Am Heart Assoc. 2014 Mar 13;3(2):e000560. doi: 10.1161/JAHA.113.000560.

8.

Clinical pharmacokinetics of second generation antisense oligonucleotides.

Yu RZ, Grundy JS, Geary RS.

Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):169-82. doi: 10.1517/17425255.2013.737320. Epub 2012 Dec 12. Review.

PMID:
23231725
9.

In vitro metabolic stabilities and metabolism of 2'-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates.

Baek MS, Yu RZ, Gaus H, Grundy JS, Geary RS.

Oligonucleotides. 2010 Dec;20(6):309-16. doi: 10.1089/oli.2010.0252. Epub 2010 Nov 30.

PMID:
21117960
10.

Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.

Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS.

Clin Pharmacokinet. 2005;44(5):517-23.

PMID:
15871637
12.

Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients.

Ragueneau-Majlessi I, Levy RH, Bergen D, Garnett W, Rosenfeld W, Mather G, Shah J, Grundy JS.

Epilepsy Res. 2004 Nov;62(1):1-11.

PMID:
15519127
13.

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.

Vollmer TL, Phillips JT, Goodman AD, Agius MA, Libonati MA, Giacchino JL, Grundy JS.

Mult Scler. 2004 Oct;10(5):511-20.

PMID:
15471366
14.
15.

Grapefruit juice and orange juice effects on the bioavailability of nifedipine in the rat.

Grundy JS, Eliot LA, Kulmatycki KM, Foster RT.

Biopharm Drug Dispos. 1998 Apr;19(3):175-83.

PMID:
9570001
16.

Extrahepatic first-pass metabolism of nifedipine in the rat.

Grundy JS, Eliot LA, Foster RT.

Biopharm Drug Dispos. 1997 Aug;18(6):509-22.

PMID:
9267683
17.
18.

Photostability determination of commercially available nifedipine oral dosage formulations.

Grundy JS, Kherani R, Foster RT.

J Pharm Biomed Anal. 1994 Dec;12(12):1529-35.

PMID:
7696377
19.

Sensitive high-performance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection.

Grundy JS, Kherani R, Foster RT.

J Chromatogr B Biomed Appl. 1994 Mar 18;654(1):146-51.

PMID:
8004237
20.

Rates of generation of methotrexate-resistant variants in cells temperature-sensitive for malignant transformation.

Chambers AF, Harris JF, Grundy JS.

Somat Cell Mol Genet. 1988 May;14(3):253-9.

PMID:
3368829

Supplemental Content

Loading ...
Support Center